NASDAQ:GNMK - GenMark Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GenMark Diagnostics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.44 +0.10 (+1.87 %) (As of 01/28/2020 06:00 AM ET) Add Compare Today's Range$5.20Now: $5.44▼$5.5350-Day Range$4.63MA: $5.08▼$5.5952-Week Range$4.47Now: $5.44▼$8.37Volume230,644 shsAverage Volume314,753 shsMarket Capitalization$315.96 millionP/E RatioN/ADividend YieldN/ABeta1.15 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNMK Previous Symbol CUSIPN/A CIK1487371 Webhttp://www.genmarkdx.com/ Phone760-448-4300Debt Debt-to-Equity Ratio6.40 Current Ratio2.69 Quick Ratio2.11Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$70.76 million Price / Sales4.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book9.07Profitability EPS (Most Recent Fiscal Year)($0.91) Net Income$-50,500,000.00 Net Margins-60.63% Return on Equity-239.16% Return on Assets-53.75%Miscellaneous Employees477 Outstanding Shares58,080,000Market Cap$315.96 million Next Earnings Date2/20/2020 (Estimated) OptionableOptionable Receive GNMK News and Ratings via Email Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GNMK Rates by TradingView GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions What is GenMark Diagnostics' stock symbol? GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK." How were GenMark Diagnostics' earnings last quarter? GenMark Diagnostics, Inc (NASDAQ:GNMK) posted its earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The medical equipment provider earned $20.92 million during the quarter, compared to analysts' expectations of $20.66 million. GenMark Diagnostics had a negative return on equity of 239.16% and a negative net margin of 60.63%. View GenMark Diagnostics' Earnings History. When is GenMark Diagnostics' next earnings date? GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for GenMark Diagnostics. What guidance has GenMark Diagnostics issued on next quarter's earnings? GenMark Diagnostics issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $88-88 million, compared to the consensus revenue estimate of $88.3 million. What price target have analysts set for GNMK? 3 analysts have issued 1 year target prices for GenMark Diagnostics' stock. Their forecasts range from $7.00 to $12.00. On average, they expect GenMark Diagnostics' share price to reach $9.67 in the next twelve months. This suggests a possible upside of 77.7% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics. What is the consensus analysts' recommendation for GenMark Diagnostics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GenMark Diagnostics. What are Wall Street analysts saying about GenMark Diagnostics stock? Here are some recent quotes from research analysts about GenMark Diagnostics stock: 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (1/8/2020) 2. Canaccord Genuity analysts commented, "We are positive on the hire of the role of SVP of Sales, adding to the company’s management team. GenMark is well positioned to execute this year as the sales force now has the new trio" of blood culture ID panels to sell. We reiterate our BUY rating and $10 price target. Q1 was a slight beat – impressive given tough Y/Y comp. Q1 revs of $21.5M (+4% Y/ Y) beat our $20.7M (flat $20.9M, which we view as solid particularly given a very difficult comp due to last year’s record influenza season. GNMK placed 39 net ePlex instruments, above our 34E. LPS of ($0.21) matched us and was in line with Street’s ($0.20). OPEX of $16.8M (+12% Y/Y) was consistent with our $16.2M. Reiterates 2019 revenue/placement guide." (5/1/2019) 3. Needham & Company LLC analysts commented, "GNMK’s 4Q18 revenue was consistent with its preannouncement while its EPS missed consensus. Management provided 2019 revenue guidance that was above consensus at the mid-point and ePlex placement guidance that was above our estimate at the mid-point. GNMK placed 42 ePlex systems in 4Q18, down from 45 in 3Q18 but above our estimate of 39. We believe the 4Q18 results provide further evidence that ePlex is gaining momentum while GNMK works out its manufacturing growing pains. We think an expanding test menu should help drive ePlex placements and utilization 2019 and we reiterate our Buy rating." (2/22/2019) Has GenMark Diagnostics been receiving favorable news coverage? Media headlines about GNMK stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GenMark Diagnostics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for GenMark Diagnostics. Are investors shorting GenMark Diagnostics? GenMark Diagnostics saw a increase in short interest in January. As of January 15th, there was short interest totalling 1,880,000 shares, an increase of 11.9% from the December 31st total of 1,680,000 shares. Based on an average daily volume of 286,600 shares, the days-to-cover ratio is currently 6.6 days. Approximately 3.5% of the shares of the stock are sold short. View GenMark Diagnostics' Current Options Chain. Who are some of GenMark Diagnostics' key competitors? Some companies that are related to GenMark Diagnostics include Shockwave Medical (SWAV), Cryolife (CRY), Tactile Systems Technology (TCMD), Luminex (LMNX), Axonics Modulation Technologies (AXNX), Orthofix Medical (OFIX), Orthopediatrics (KIDS), Intersect ENT (XENT), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), Cerus (CERS), Anika Therapeutics (ANIK), SI-Bone (SIBN), AngioDynamics (ANGO) and SurModics (SRDX). What other stocks do shareholders of GenMark Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include NovaBay Pharmaceuticals (NBY), Rigel Pharmaceuticals (RIGL), T2 Biosystems (TTOO), Biocept (BIOC), Amicus Therapeutics (FOLD), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), VBI Vaccines (VBIV) and Catalyst Pharmaceuticals (CPRX). Who are GenMark Diagnostics' key executives? GenMark Diagnostics' management team includes the folowing people: Mr. Hany Massarany, CEO, Pres & Director (Age 58)Mr. Scott Mendel, Chief Operating Officer (Age 52)Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)Mr. John Frederick Ek, Chief Financial Officer (Age 43)Mr. Eric Stier, Sr. VP, Gen. Counsel & Sec. (Age 43) Who are GenMark Diagnostics' major shareholders? GenMark Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.19%) and Alpine Global Management LLC (0.05%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael Kagnoff, Sarah Hollis Winkler, Scott Mendel and Tyler Jensen. View Institutional Ownership Trends for GenMark Diagnostics. Which major investors are buying GenMark Diagnostics stock? GNMK stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Alpine Global Management LLC. View Insider Buying and Selling for GenMark Diagnostics. How do I buy shares of GenMark Diagnostics? Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is GenMark Diagnostics' stock price today? One share of GNMK stock can currently be purchased for approximately $5.44. How big of a company is GenMark Diagnostics? GenMark Diagnostics has a market capitalization of $315.96 million and generates $70.76 million in revenue each year. The medical equipment provider earns $-50,500,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe.View Additional Information About GenMark Diagnostics. What is GenMark Diagnostics' official website? The official website for GenMark Diagnostics is http://www.genmarkdx.com/. How can I contact GenMark Diagnostics? GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected] MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 492 (Vote Outperform)Underperform Votes: 295 (Vote Underperform)Total Votes: 787MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: Does a trade war provide a risk to the global economy?
